CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 70 enrolled
Drug / intervention
Guanfacine 3mg/day +2 moredrug
Likely dose
Guanfacine 3mg/dayfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02164422
NCT02164422Phase 2Completed
CompareCT.gov

Does Guanfacine Attenuate Stress-Induced Drinking?

Yale University·interventional·Posted Jun 16, 2014·Updated Jul 8, 2021

In Brief

A Phase 2 clinical trial evaluating Guanfacine 3mg/day, Guanfacine 1.5mg/day, and 1 other intervention for Alcohol Drinking. Completed, enrolled 70 participants across 1 site.

Detailed Summary

Evaluating the effect of guanfacine on alcohol consumption. The investigators hypothesize that guanfacine versus placebo will decrease the amount of alcohol consumption (mls consumed) during the 2-hour self-administration period across two laboratory sessions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Drinking
CountriesUnited States
CollaboratorsNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 16, 2014
Enrollment StartJun 1, 2014
Primary CompletionMar 31, 2020
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 12.0 years ago

Interventions

Guanfacine 3mg/daydrug

3 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.

Guanfacine 1.5mg/daydrug

1.5 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.

Placebodrug